1. Inhaled particles containing a stabilized anhydrous amorphous form of tiotropium with a stabilizing agent, which is a sugar derivative. 2. Inhaled particles according to claim 1, wherein tiotropium contains tiotropium bromide. 3. The respirable particles of claim 1, wherein the sugar derivative is lactose. Inhaled particles according to claim 1, having an average aerodynamic particle size of not more than 10 μm. The respirable particles of claim 1, wherein the stabilized amorphous form of tiotropium with a stabilizing agent contains a matrix in which tiotropium is distributed at the molecular level. The respirable particles of claim 1, wherein the stabilized amorphous form of tiotropium with a stabilizing agent contains amorphous tiotropium distributed over the surface of the stabilizing agent. The respirable particles of claim 1, wherein the particles are mixed with one or more coarse particulate fillers having an average particle size of 15 to 250 microns. The respirable particles of claim 7, wherein the coarse particulate filler is lactose. A pharmaceutical composition containing inhaled particles according to claim 5.10. The pharmaceutical composition of claim 9, wherein the tiotropium base content is from 0.02 to 0.8%. 11. The pharmaceutical composition of claim 9 in the form of a capsule for inhalation. The pharmaceutical composition of claim 11, wherein the capsule contains hydroxypropyl methylcellulose. A method for producing respirable particles according to claim 1, comprising the steps of: a) dissolving or dispersing a stabilizing agent in a volatile water-miscible solvent, optionally containing water, to form a solution or suspension； b) dissolving a tiotropium salt or solvate thereof, or any1. Вдыхаемые частицы, содержащие стабилизированную безводную аморфную форму тиотропия со стабилизирующим агентом, который представляет собой производное сахара.2. Вдыхаемые частицы по п. 1, где тиотропий содержит тиотропий бромид.3. Вдыхаемые частицы по п. 1, где
